1. What Is the Point of Care Molecular Diagnostics Market?
The Point of Care Molecular Diagnostics Market covers near-patient amplification systems enabling rapid PCR and isothermal pathogen detection for respiratory, STI, and sepsis at clinics and EDs. POC molecular diagnostics encompasses cartridge-based PCR, LAMP isothermal, NAAT, and multiplex molecular panel systems. Market dynamics reflect COVID-19 establishing POC molecular testing infrastructure, respiratory multiplex panel adoption enabling influenza-RSV-COVID single test diagnosis, and GI and STI POC molecular tests reducing laboratory send-out turnaround time.
2. Point of Care Molecular Diagnostics Market Size & Forecast
3. Emerging Technologies
- POC NAAT sexually transmitted infection panels enabling same-visit diagnosis and treatment of gonorrhoea and chlamydia are advancing as STI care tools. Growing adoption at sexual health clinics is driven by same-visit treatment initiation and contact tracing requirements.
- Handheld smartphone-connected molecular diagnostic systems enabling POC molecular testing in low-resource settings are advancing as access tools. Growing adoption at global health programmes is driven by HIV, TB, and malaria molecular diagnosis requirements in resource-limited settings.
- Sepsis molecular blood culture PCR panels reducing sepsis pathogen identification from 48 hours to 90 minutes are advancing as critical care tools. Growing adoption at ICU and ED programmes is driven by targeted antibiotic therapy initiation requirements.
- Hospital infection surveillance molecular platforms tracking resistance gene spread across inpatient units are advancing as stewardship tools. Growing adoption is driven by CRE and MRSA nosocomial infection prevention requirements.
Similar technologies are also transforming adjacent markets. Learn more in our Point Of Care Immunoassay Market.
4. Key Market Opportunity
The primary growth driver in the Point of Care Molecular Diagnostics Market is the respiratory multiplex panel sub-market, where BioFire and Cepheid annual influenza season test volume creates recurring high-margin cartridge revenue. STI molecular POC creates a growing sexual health opportunity as same-visit diagnosis and treatment models reduce STI burden. Sepsis molecular rapid diagnosis creates a premium ICU opportunity as 90-minute pathogen identification versus 48-hour blood culture justifies POC molecular investment. Asia Pacific POC molecular creates geographic expansion as Chinese, Japanese, and Indian ED and primary care molecular adoption grows.
5. Top Companies in the Point of Care Molecular Diagnostics Market
The following organisations hold leading positions in the Point of Care Molecular Diagnostics Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Cepheid (GeneXpert)
- bioMerieux (BioFire)
- Abbott (ID NOW)
- Roche (cobas Liat)
- Hologic (Panther)
- GenMark (ePlex)
- Curetis (Unyvero)
- Qiagen (QIAsymphony)
- Diasorin (Simplexa)
- Genalyte
6. Market Segmentation
The Point of Care Molecular Diagnostics Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Technology | PCR Cartridge LAMP Isothermal Multiplex NAAT Digital PCR |
| By Application | Respiratory Panel STI NAAT Sepsis Molecular GI Panel Hospital Infection |
| By Setting | ED Urgent Care Primary Care Clinic GP Office Pharmacy |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Point of Care Molecular Diagnostics Market trajectory over the forecast period:
Cepheid GeneXpert Infinity Achieves 30,000 System Installations as Global POC Molecular Market Leader.Cepheid GeneXpert achieving 30,000 system installations globally in 2024 demonstrates POC molecular diagnostics at the most widely deployed molecular instrument platform. Cepheid respiratory panel testing influenza A and B, RSV, SARS-CoV-2, and metapneumovirus from a single cartridge demonstrates the multiplex panel advantage driving POC molecular adoption.
Abbott ID NOW COVID Influenza RSV Achieves 10-Minute Result in Primary Care Setting.Abbott ID NOW isothermal amplification achieving 10-minute result turnaround for COVID-19, influenza, and RSV from a single nasal swab demonstrates isothermal POC molecular at primary care speed requirements. Abbott ID NOW achieving 50 million tests annually demonstrates isothermal molecular diagnostics at consumer-scale POC test volume.
bioMerieux BioFire FilmArray Multiplex Achieves ED Standard-of-Care for Respiratory Panel Testing.BioFire FilmArray RP2 achieving standard-of-care for ED respiratory panel testing at 3,000 US emergency departments in 2024 demonstrates multiplex POC molecular at acute care standard. BioFire RP2 differentiating bacterial pneumonia requiring antibiotics from viral respiratory infection avoiding unnecessary antibiotic prescription demonstrates antimicrobial stewardship clinical value.
For related market intelligence, see the Immunoassay Market.
8. Segmental Analysis
By technology, the PCR Cartridge and Multiplex NAAT segment dominated the Point of Care Molecular Diagnostics Market in 2025. Representing the largest revenue category as Cepheid GeneXpert and BioFire achieve ED standard-of-care. The Isothermal LAMP segment is the fastest-growing category, advancing as Abbott ID NOW 10-minute result drives primary care adoption.
By application, the Respiratory Panel segment dominated the Point of Care Molecular Diagnostics Market in 2025. Representing the largest application revenue share. The STI NAAT segment is the fastest-growing application category, advancing as clinical protocol standardisation and reimbursement expansion broaden market access. The STI NAAT growth rate is outpacing the overall Point of Care Molecular Diagnostics Market average, gradually shifting application revenue composition through 2034.
By setting, the Emergency Department and Urgent Care segment dominated the Point of Care Molecular Diagnostics Market in 2025, as rapid respiratory pathogen panel testing and sepsis marker molecular assays in emergency settings generate the highest POC molecular diagnostic revenue. Primary Care Clinic is the fastest-growing setting category, driven by CLIA-waived molecular POC devices enabling rapid strep, influenza, and RSV testing outside hospital-based settings.
9. Regional Analysis
Regional demand patterns across the Point of Care Molecular Diagnostics Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Point of Care Molecular Diagnostics Market in 2025, holding 48.6% of the global market. Emergency physicians, infectious disease specialists, and point-of-care testing operators are deploying molecular diagnostic platforms for rapid pathogen identification, antimicrobial resistance genotyping, and respiratory virus panel testing at the point of care. FDA Emergency Use Authorisation experience and growing 510(k) clearances for point-of-care molecular diagnostics, combined with CMS reimbursement for decentralised molecular testing, are encouraging clinical adoption. High infectious disease diagnosis volumes, established molecular testing market, and strong physician demand for rapid actionable results are generating regional demand.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 17.05% during the forecast period. Emergency departments, primary care clinics, and point-of-care testing networks across China, India, Japan, and Southeast Asia are deploying molecular diagnostics platforms to enable rapid pathogen identification in settings without central laboratory access. Government infectious disease surveillance investment and growing demand for rapid molecular testing in community health settings are creating institutional demand for point-of-care molecular diagnostic platforms. Rising demand for antimicrobial stewardship-generating rapid diagnostics and increasing deployment of molecular testing outside hospital laboratory settings are generating demand.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Point of Care Molecular Diagnostics Market was valued at USD 4.52 Bn in 2025 and is projected to reach USD 15.06 Bn by 2034, growing at a CAGR of 14.3% over the 2026–2034 forecast period.
The Point of Care Molecular Diagnostics Market is projected to grow at a CAGR of 14.3% from 2026 to 2034.
North America accounted for the largest share of the Point of Care Molecular Diagnostics Market in 2025, holding 48.6% of the global market.
The leading companies in the Point of Care Molecular Diagnostics Market include Cepheid (GeneXpert), bioMerieux (BioFire), Abbott (ID NOW), Roche (cobas Liat), Hologic (Panther), GenMark (ePlex), Curetis (Unyvero), Qiagen (QIAsymphony), Diasorin (Simplexa), Genalyte.
Cepheid genexpert infinity achieves 30,000 system installations as global poc molecular market leader.
By technology, the PCR Cartridge and Multiplex NAAT segment dominated the Point of Care Molecular Diagnostics Market in 2025.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.